Sasaya Miyu, Takei Daisuke, Abe Tomoya, Hiraide Makoto, Torigoe Kazuhiro, Nakayama Toshiaki, Otsuka Masanobu, Sano Motohiko
Laboratory of Clinical Pharmacy Assessment, Hoshi University, Tokyo 142-8501, Japan.
Pharmaceutical Department, Saitama Cancer Center, Ina, Saitama 362-0806, Japan.
Mol Clin Oncol. 2025 May 15;23(1):63. doi: 10.3892/mco.2025.2858. eCollection 2025 Jul.
Real-world data on the effectiveness of anamorelin in managing cancer cachexia remains limited, particularly as its availability is currently restricted to Japan. In the present study, anamorelin use in cancer cachexia management was retrospectively evaluated, focusing on patient characteristics and survival after both short- and long-term use. Patients prescribed anamorelin between August 2021 and January 2024 at the Saitama Canc2er Center (Ina, Japan) were included. Medical records were reviewed to collect baseline characteristics at anamorelin treatment initiation. The patients were divided into two groups: short- and long-treatment groups (STT and LTT, respectively). Overall, 60 and 69 patients were included in the STT and LTT groups, respectively. Significant intergroup differences were found in age (P=0.021), gastric cancer incidence rate (P=0.013), albumin level of <3.5 g/dl (P=0.044) and Eastern Cooperative Oncology Group performance status score (P=0.008). The longest median time from diagnosis to anamorelin treatment initiation was observed for colorectal cancer, while the longest median anamorelin treatment duration was observed for lung cancer. The median survival durations during anamorelin treatment were 49 and 142 days in the STT and LTT groups, respectively (P<0.001). The corresponding median survival durations after anamorelin treatment termination in the STT and LTT groups were 38 and 34 days (P=0.554), respectively. Anamorelin treatment duration influenced patient survival, with post-discontinuation survival being ~1 month, regardless of treatment length.
关于阿那莫林治疗癌症恶病质有效性的真实世界数据仍然有限，尤其是因为其目前仅在日本可用。在本研究中，对阿那莫林在癌症恶病质管理中的应用进行了回顾性评估，重点关注患者特征以及短期和长期使用后的生存情况。纳入了2021年8月至2024年1月期间在埼玉癌症中心（日本伊奈）开具阿那莫林处方的患者。查阅医疗记录以收集阿那莫林治疗开始时的基线特征。患者分为两组：短期治疗组和长期治疗组（分别为STT和LTT）。总体而言，STT组和LTT组分别纳入了60例和69例患者。在年龄（P = 0.021）、胃癌发病率（P = 0.013）、白蛋白水平<3.5 g/dl（P = 0.044）和东部肿瘤协作组体能状态评分（P = 0.008）方面发现了显著的组间差异。从诊断到开始使用阿那莫林的最长中位时间在结直肠癌中观察到，而阿那莫林最长中位治疗持续时间在肺癌中观察到。在STT组和LTT组中，阿那莫林治疗期间的中位生存时间分别为49天和142天（P < 0.001）。STT组和LTT组在阿那莫林治疗终止后的相应中位生存时间分别为38天和34天（P = 0.554）。阿那莫林治疗持续时间影响患者生存，无论治疗时长如何，停药后的生存时间约为1个月。
